Hansoh Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hansoh Pharmaceutical - overview
Established
2018
Location
Hong Kong, -, Hong Kong SAR - China
Primary Industry
Pharmaceuticals
About
Established in 2018 and based in Hong Kong, China, Hansoh Pharmaceutical operates as a drug developer that mainly provides anti-tumor and psychiatric drugs. It is an equity holding platform that holds a company called Jiangsu Hansoh Pharmaceutical Group Co. , Ltd, which mainly engages in drug research and development, manufacturing, and sales. In May 2019, Boyu Capital, Hillhouse Capital Group, Ally Bridge, and other investors bid to acquire Jiangsu Hansoh Pharmaceutical Co.
, Ltd. during the IPO. In June 2019, the company was listed on the Hong Kong Stock Exchange. The company focuses on the research and development and production of drugs.
The drugs include anti-tumor drugs, central nervous system drugs, anti-infective drugs, metabolic and other disease drugs. The products involve five fields, which are anti-tumor, mental, diabetes, digestive tract and antibiotics. Anti-tumor drugs include ametinib mesylate tablets and flumatinib mesylate tablets. Hansoh Pharmaceutical also provides drug consulting and product services.
The company generates revenue by providing anti-tumor and psychiatric drugs.
Current Investors
OrbiMed Advisors, GIC, Vivo Capital
Primary Industry
Pharmaceuticals
Sub Industries
Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.hansoh.cn
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Hansoh Pharmaceutical - financials
| Fiscal Year Ended | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Revenue (USD) | 5,432,960,000 | 6,185,537,000 | 7,722,278,000 | - | - | - |
| % Revenue Growth (YoY) | - | 13.9% | 24.8% | - | - | - |
| EBITDA (USD) | 1,923,315,000 | 2,068,137,000 | 2,465,590,000 | - | - | - |
| Operating Income (USD) | 1,804,278,000 | 1,932,791,000 | 2,309,325,000 | - | - | - |
| Operating Margin | 33.2% | 31.2% | 29.9% | - | - | - |
| % EBITDA Margin | 35.4% | 33.4% | 31.9% | - | - | - |
| NET Income (USD) | 1,476,034,000 | 1,595,473,000 | 1,903,048,000 | - | - | - |
| % Net Margin | 27.2% | 25.8% | 24.6% | - | - | - |
Hansoh Pharmaceutical - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A | Completed | Blossom Bioscience | - | ||||||||
| PIPE | Completed | Hansoh Pharmaceutical | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.